Med compliance could save $290B yearly

If patients just took their meds as directed, pharma sales would grow significantly. That's why drugmakers have been trying all sorts of ways to remind folks to take their pills: mailings from the pharmacy, emails, you name it.

Maybe the government should join in on the compliance push. After all, cutting healthcare costs is one of the big aims of the U.S. reform push right now. And a new study shows that medication compliance could save the U.S. $290 billion a year, or 13 percent of total healthcare costs. That's because so many of today's drugs address chronic conditions and, ironically, people with chronic illness are worst at taking their meds. And by skipping drugs, chronically ill folks experience complications that then have to be treated, often in the hospital.

For instance, PharmaTimes reports, diabetics who don't take their meds as directed have almost twice the total annual healthcare costs as those who do, at $16,498 compared with $8,886. Considering how many people have diabetes in the U.S., that difference could total quite a sum.

- read the PharmaTimes story
- see the item at PharmaGossip

Suggested Articles

One year after its landmark Reduce-It CV outcomes trial, Amarin has new data showing its Vascepa may help halt the progress of arterial plaque.

Amgen could soon face new competition in the PCSK9 class, but an efficacy boost in treating high-risk heart attack patients could help keep it ahead.

In its quest to become the dominant SGLT2 diabetes med for heart failure, Jardiance is touting DPP-4 inhibitor-topping data to support its case.